← SEC 公告列表 | AXSM SEC 公告 | AXSOME THERAPEUTICS INC COM USD0.0001(AXSM)

重大事件 即時報告 8-K 2026-06-09

本摘要基於公開申報文件整理,不構成投資建議。

於 SEC 網站開啟原文

AI 繁中摘要

Axsome Therapeutics, Inc. 於2026年6月9日向SEC提交8-K申報文件,報告日期為2026年6月5日。是次申報主要涉及兩項內容:第一,根據Item 5.02,公司披露了董事或特定高級職員的離職、選舉或任命,以及相關的補償安排;第二,根據Item 9.01,提交了相關財務報表及附件。公司同時上載了一份重要的補償協議(EX-10.1),但文件中未有披露具體人員變動細節或財務影響。 📌 對投資者的潛在影響:高層人事變動或補償安排可能反映公司內部管理層的調整,短期內或影響市場對管理穩定性的預期。投資者應留意公司未來公告以了解變動原因及對研發進度、商業化策略的潛在影響。 *本摘要基於公開申報文件整理,不構成投資建議。*
展開英文正文
EDGAR Filing Documents for 0001193125-26-264047

 
 
 
 
 
 
 

 
 
 SEC.gov
 
 

 
 EDGAR
 

 

 
 
 Latest Filings 
 

 
 Filings search tools
 

 
 
 Filing Detail

 
 SEC Home »

 Company Search »

 Current Page

 

 
 
 Form 8-K - Current report: 
 

 
 SEC Accession No. 0001193125-26-264047
 

 

 
 
 
 Filing Date

 2026-06-09

 Accepted

 2026-06-09 17:20:47

 Documents

 10

 

 
 Period of Report

 2026-06-05

 

 
 Items

 Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

 

 

 
  Interactive Data
 

 

 

 
 Document Format Files

 
 
 Seq
 Description
 Document
 Type
 Size
 

 
 1
 8-K
 axsm-20260605.htm   iXBRL
 8-K
 50691
 

 
 2
 EX-10.1
 axsm-ex10_1.htm
 EX-10.1
 288083
 

 
  
 Complete submission text file
 0001193125-26-264047.txt
  
 488556
 

 
 

 
 Data Files

 
 
 Seq
 Description
 Document
 Type
 Size
 

 
 3
 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
 axsm-20260605.xsd
 EX-101.SCH
 23858
 

 
 13
 EXTRACTED XBRL INSTANCE DOCUMENT
 axsm-20260605_htm.xml
 XML
 4543
 

 
 

 Mailing Address
 ONE WORLD TRADE CENTER, 29TH FLOOR
 
NEW YORK NY
10007 
 

 Business Address
 ONE WORLD TRADE CENTER, 29TH FLOOR
 
NEW YORK NY
10007 
 (212) 332-3241
 

 Axsome Therapeutics, Inc. (Filer)
 CIK: 0001579428 (see all company filings)
EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 261077178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)